Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Samson

Showing results (11-20 of 181) with videos related to

Pageof 19
Sort By:
La Revue Du Praticien|June 8, 2023
[Diagnosis of giant cell arteritis]Hélène Greigert, Bernard Bonnotte, Maxime Samson
La Revue Du Praticien|June 8, 2023
[Epidemiology and pathophysiology of giant cell arteritis]Hélène Greigert, Bernard Bonnotte, Maxime Samson
Mediators of Inflammation|January 12, 2017
Immunotherapeutic Targeting in Autoimmune DiseasesNona Janikashvili, Maxime Samson, Eli Magen, et al.
Presse Medicale (Paris, France : 1983)|July 21, 2019
[Treatment of giant cell arteritis]Maxime Samson, Hélène Greigert, Thibault Ghesquière, et al.
Annals of the Rheumatic Diseases|August 31, 2013
Is TNF-α really involved in giant cell arteritis pathogenesis?Maxime Samson, Sylvain Audia, Nona Janikashvili, et al.
Joint Bone Spine|January 2, 2022
Targeted treatment in Takayasu arteritisMaxime Samson, Hélène Greigert, André Ramon, et al.
Annals of the Rheumatic Diseases|March 12, 2013
Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et alMaxime Samson, Sylvain Audia, Nona Janikashvili, et al.
Annals of the Rheumatic Diseases|May 15, 2017
Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritisMaxime Samson, Thibault Ghesquière, Sabine Berthier, et al.
Expert Opinion on Biological Therapy|May 19, 2026
Relapse in giant cell arteritis: challenges after discontinuation of targeted therapiesMarco Alba, Gary Reynolds, Maxime Samson, et al.
Modern Rheumatology|December 7, 2016
Treatment of giant-cell arteritis, a literature reviewBénédicte Watelet, Maxime Samson, Hubert de Boysson, et al.
Pageof 19

Showing results (11-20 of 181) with videos related to

Sort By:
Pageof 19
La Revue Du Praticien|June 8, 2023
[Diagnosis of giant cell arteritis]Hélène Greigert, Bernard Bonnotte, Maxime Samson
La Revue Du Praticien|June 8, 2023
[Epidemiology and pathophysiology of giant cell arteritis]Hélène Greigert, Bernard Bonnotte, Maxime Samson
Mediators of Inflammation|January 12, 2017
Immunotherapeutic Targeting in Autoimmune DiseasesNona Janikashvili, Maxime Samson, Eli Magen, et al.
Presse Medicale (Paris, France : 1983)|July 21, 2019
[Treatment of giant cell arteritis]Maxime Samson, Hélène Greigert, Thibault Ghesquière, et al.
Annals of the Rheumatic Diseases|August 31, 2013
Is TNF-α really involved in giant cell arteritis pathogenesis?Maxime Samson, Sylvain Audia, Nona Janikashvili, et al.
Joint Bone Spine|January 2, 2022
Targeted treatment in Takayasu arteritisMaxime Samson, Hélène Greigert, André Ramon, et al.
Annals of the Rheumatic Diseases|March 12, 2013
Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et alMaxime Samson, Sylvain Audia, Nona Janikashvili, et al.
Annals of the Rheumatic Diseases|May 15, 2017
Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritisMaxime Samson, Thibault Ghesquière, Sabine Berthier, et al.
Expert Opinion on Biological Therapy|May 19, 2026
Relapse in giant cell arteritis: challenges after discontinuation of targeted therapiesMarco Alba, Gary Reynolds, Maxime Samson, et al.
Modern Rheumatology|December 7, 2016
Treatment of giant-cell arteritis, a literature reviewBénédicte Watelet, Maxime Samson, Hubert de Boysson, et al.
Pageof 19